“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting - Episode 2

Updates in Relapsed/Refractory Myeloma

January 29, 2021
Ajai Chari, MD, Mount Sinai Hospital

,
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center

,
Saad Z. Usmani, MD, FACP, Levine Cancer Institute

,
Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Important considerations regarding the sequencing of IMid–versus–PI-based approaches for relapsed/refractory multiple myeloma based on updates presented at the ASH 2020 Virtual Meeting.

Data from the following presentations are discussed:

  • Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 CANDOR study. (Dimopoulos, ASH 2020 Abstract 2325)
    • Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 CANDOR Study in Patients With Early or Late Relapse. (Weisel, ASH 2020 Abstract 2287)

    • Evaluation of Minimal Residual Disease (MRD) Negativity in Patients With Relapsed or Refractory Multiple Myeloma Treated in the CANDOR Study. (Landgren, ASH 2020 Abstract 2282)

  • Isatuxumab Plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-label Study. (Moreau, ASH 2020 Abstract 2316)

  • APOLLO: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). (Dimopoulos, ASH 2020 Abstract 412)

  • A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. (Sebag, ASH 2020, Abstract 413)

x